236 related articles for article (PubMed ID: 16183119)
1. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
[TBL] [Abstract][Full Text] [Related]
3. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.
Hartmann K; Wardelmann E; Ma Y; Merkelbach-Bruse S; Preussner LM; Woolery C; Baldus SE; Heinicke T; Thiele J; Buettner R; Longley BJ
Gastroenterology; 2005 Sep; 129(3):1042-6. PubMed ID: 16143141
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
6. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
7. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
Mital A; Piskorz A; Lewandowski K; Wasąg B; Limon J; Hellmann A
Eur J Haematol; 2011 Jun; 86(6):531-5. PubMed ID: 21362052
[TBL] [Abstract][Full Text] [Related]
8. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
9. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
Cairoli R; Beghini A; Morello E; Grillo G; Montillo M; Larizza L; Morra E
Leuk Res; 2005 Apr; 29(4):397-400. PubMed ID: 15725473
[TBL] [Abstract][Full Text] [Related]
11. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
12. Not all c-kit mutations can be corrected by imatinib.
Lasota J
Lab Invest; 2007 Apr; 87(4):317. PubMed ID: 17486696
[No Abstract] [Full Text] [Related]
13. Imatinib in melanoma: a selective treatment option based on KIT mutation status?
Becker JC; Bröcker EB; Schadendorf D; Ugurel S
J Clin Oncol; 2007 Mar; 25(7):e9. PubMed ID: 17327598
[No Abstract] [Full Text] [Related]
14. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
15. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
16. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
17. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
19. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
20. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
